JPMorgan Chase & Co. downgraded Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to Neutral in a statement released earlier today.
- Updated: October 5, 2016
Boasting a price of $70.30, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) traded 2.52% higher on the day. With the last stock price close up 5.78% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Alnylam Pharmaceuticals, Inc. has recorded a 50-day average of $72.86 and a two hundred day average of $66.46. Trading volume was up over the average, with 1,965,395 shares of ALNY changing hands over the typical 643,269
JPMorgan Chase & Co. has downgraded Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to Neutral in a report released on 10/6/2016.
On Thursday September 29, 2016, Janney Capital released a statement for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) bumped up the target price from $0.00 to $74.00 that suggested a downside of -0.03%.
With a total market value of $0, Alnylam Pharmaceuticals, Inc. has 52 week low of $49.96 and a 52 week high of $110.75 .
In addition to JPMorgan Chase & Co. reporting its stock price target, a total of 11 brokers have issued a research note on the company. The average stock price target is $117.09 with 3 brokers rating the stock a strong buy, 8 brokers rating the stock a buy, 2 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease. Its Genetic medicines include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), Fitusiran (ALN-AT3), ALN-CC5, ALN-AS1, and additional genetic programs, including ALN-AAT, ALN-GO1 and ALN-TMP. Products for Cardio-Metabolic Disease STAr include ALN-PCSsc and other cardio-metabolic disease programs ALN-AC3 and ALN-ANG targeting Angiopoetin-like 3 (ANGPTL3). Products for Hepatic Infectious Disease STAr include ALN-HBV, ALN-HDV and ALN-PDL. It also owns Enhanced Stabilization Chemistry, GalNAc-conjugate delivery platform.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.